+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Matrix metalloproteinases 2 and 9 in equine synovial fluids



Matrix metalloproteinases 2 and 9 in equine synovial fluids



Equine Veterinary Journal 29(5): 343-348



Matrix metalloproteinases (MMPs) may be important in the destruction of cartilage seen in equine osteoarthritis and may be detectable in synovial fluid. Synovial fluids were obtained from normal equine joints and from joints of horses with aseptic and septic joint diseases. The total gelatinase enzyme activities were measured by gelatin zymography and image analysis of the gets. The bioactivity of gelatinase in synovial fluid was determined by a gelatin degradation ELISA. Potential MMP-2 and MMP-9 monomer enzyme activities were significantly elevated in both septic and aseptic joint disease synovial fluids in comparison to fluids from normal joints. The dimer form of MMP-9 enzyme activity was significantly elevated in fluids from septic joint disease cases in comparison to fluids from normal joints, but not fluids from horses with aseptic joint diseases. MMP-9 monomer and dimer levels in synovial fluids correlated with the synovial fluid white blood cell count. Using the gelatin degradation ELISA to measure net active gelatinases, significant increases in gelatinase bioactivities were seen in synovial fluids from both aseptic and septic joint disease cases. The enzymes in equine joint diseases were present in a bioactive form, in that they were present in the activated form and present in excess of inhibitors, and could therefore be important in the degradation of articular cartilage in joint disease.

(PDF emailed within 0-6 h: $19.90)

Accession: 002891576

Download citation: RISBibTeXText

PMID: 9306059

DOI: 10.1111/j.2042-3306.1997.tb03137.x


Related references

Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis. Annals of the Rheumatic Diseases 59(6): 455-461, 2000

Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids of patients with temporomandibular joint osteoarthritis. Journal of Orofacial Pain 14(1): 20-30, 2001

Matrix metalloproteinases 2 and 9 activity in bovine synovial fluids. Journal of Veterinary Medicine Series A 47(8): 449-456, 2000

Expression of matrix metalloproteinases and aggrecanase in the synovial fluids of patients with symptomatic temporomandibular disorders. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics 102(1): 22-27, 2006

Matrix metalloproteinases MMP-3 and MMP-1 levels in sera and synovial fluids in patients with rheumatoid arthritis and osteoarthritis. Italian Journal of Biochemistry 54(3-4): 248-257, 2006

Expression and activity profiling of selected cysteine cathepsins and matrix metalloproteinases in synovial fluids from patients with rheumatoid arthritis and osteoarthritis. Biological Chemistry 391(5): 571-579, 2010

Measurement of cartilage oligomeric matrix protein (COMP) in normal and diseased equine synovial fluids. Osteoarthritis and Cartilage 9(2): 119-127, 2001

Immunohistochemical study of matrix metalloproteinases-2 and -9, macrophage inflammatory protein-2 and tissue inhibitors of matrix metalloproteinases-1 and -2 in normal, purulonecrotic and fungal infected equine corneas. Veterinary Ophthalmology 13(2): 81-90, 2010

Relationships of matrix metalloproteinases and their inhibitors to cartilage proteoglycan and collagen turnover and inflammation as revealed by analyses of synovial fluids from patients with rheumatoid arthritis. Arthritis and Rheumatism 44(11): 2503-2511, 2001

Evaluation of the influence of prostaglandin E2 on recombinant equine interleukin-1b-stimulated matrix metalloproteinases 1, 3, and 13 and tissue inhibitor of matrix metalloproteinase 1 expression in equine chondrocyte cultures. American Journal of Veterinary Research 63(7): 7-93, 2002

Evaluation of the influence of prostaglandin E2 on recombinant equine interleukin-1beta-stimulated matrix metalloproteinases 1, 3, and 13 and tissue inhibitor of matrix metalloproteinase 1 expression in equine chondrocyte cultures. American Journal of Veterinary Research 63(7): 987-993, 2002

Levels of matrix metalloproteinase (MMP)-1 in paired sera and synovial fluids of juvenile idiopathic arthritis patients: relationship to inflammatory activity, MMP-3 and tissue inhibitor of metalloproteinases-1 in a longitudinal study. Rheumatology 44(11): 1383-1389, 2005

Matrix metalloproteinases, tissue inhibitors of metalloproteinases, and glycosaminoglycans in synovial fluid from patients with rheumatoid arthritis. Journal of Rheumatology 26(1): 34-40, 1999

Molecular studies of matrix metalloproteinases and tissue inhibitors of metalloproteinases in equine joints. Veterinary Journal 157(3): 336-338, 1999